(By Ed Silverman for STAT)
More than a year after spending roughly $17 billion to acquire Hospira, Pfizer is finding that curing the manufacturing woes at the company is not going to be easy. The big drug maker recently halted production at a plant near Chennai, India, after inspectors from several regulatory agencies, including the US Food and Drug Administration, found various quality control problems. Continue reading article here…..
Notice: The link provided above connects readers to the full content of the posted article. The URL (internet address) for this link is valid on the posted date; medicarereport.org cannot guarantee the duration of the link’s validity. Also, the opinions expressed in these postings are the viewpoints of the original source and are not explicitly endorsed by AMAC, Inc.; the AMAC Foundation, Inc.; or medicarereport.org.